Mechanism of Action of Digoxin as an Inotrope

Primary Cardiac Mechanism

Digoxin inhibits sodium-potassium (Na-K) adenosine triphosphatase (ATPase) in cardiac cells, which leads to increased intracellular calcium concentration and enhanced myocardial contractility, while also providing neurohormonal benefits through vagal afferent sensitization and sympathetic inhibition 1, 2, 3

Digoxin inhibits Na-K ATPase in vagal afferent fibers, sensitizing cardiac baroreceptors, and reduces sympathetic outflow from the central nervous system, leading to decreased activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect) 1, 2, 3
Recent evidence suggests that digoxin's benefits in heart failure may be related more to these neurohormonal effects than to its positive inotropic action 1, 3

Digoxin inhibits Na-K ATPase in the kidney, reducing renal tubular reabsorption of sodium, and increases sodium delivery to distal tubules, leading to suppression of renin secretion 1, 2, 3

Digoxin improves symptoms, quality of life, and exercise tolerance in patients with heart failure by increasing cardiac output, improving hemodynamics, and reducing pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic vascular resistance 1, 3

Women may be more sensitive to digoxin's effects and may require lower doses to achieve therapeutic benefits 5
Understanding digoxin's dual mechanism—both as a direct cardiac inotrope and as a neurohormonal modulator—explains its unique position in heart failure management, particularly for patients with persistent symptoms despite standard therapy 1, 3